Perceptive Advisors’s Contineum Therapeutics CTNM Stock Holding History

Perceptive Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.6M	Hold	1,255,592	–	–	0.31%	61
2026 Q1	$16.4M	Sell	1,255,592 -209,000	-14%	-$2.8M	0.32%	58
2025 Q4	$16.7M	Buy	1,464,592 +750,000	+105%	+$8.56M	0.3%	67
2025 Q3	$8.4M	Buy	714,592 +15,106	+2%	+$122K	0.24%	62
2025 Q2	$2.78M	Sell	699,486 -741,763	-51%	-$3.22M	0.1%	70
2025 Q1	$10.1M	Hold	1,441,249	–	–	0.36%	54
2024 Q4	$21.1M	Sell	1,441,249 -75,419	-5%	-$1.19M	0.58%	40
2024 Q3	$29M	Sell	1,516,668 -50,000	-3%	-$959K	0.61%	40
2024 Q2	$27.6M	Buy	+1,566,668	New	+$25.2M	0.66%	44

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Perceptive Advisors's CTNM Position: Q2 2026 in Review

Perceptive Advisors held its Contineum Therapeutics (CTNM) position steady in Q2 2026 at 1,255,592 shares worth $20.6M. The position accounts for 0.31% of the portfolio, ranked #61.

Perceptive Advisors first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. The position peaked at $29M in Q3 2024. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Perceptive Advisors held 1,255,592 shares of Contineum Therapeutics worth $20.6M as of Q2 2026.
Perceptive Advisors left its Contineum Therapeutics share count unchanged in Q2 2026.
Contineum Therapeutics made up 0.31% of Perceptive Advisors's portfolio in Q2 2026, its #61 holding.
Perceptive Advisors first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
Perceptive Advisors's Contineum Therapeutics position peaked at $29M in Q3 2024.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.